Cardiosense names medtech veteran John Martin chief medical officer

Cardiosense monitor: ©Cardiosense

Cardiosense has appointed John Martin, MD, MBA, as executive vice president and chief medical officer, the medical AI company announced.

Martin, a practicing vascular surgeon and veteran health technology executive, will lead clinical development and product strategy as the company advances its regulatory efforts and prepares for commercial launch.

“John’s rare combination of clinical expertise and medtech leadership is precisely what Cardiosense needs during this transformative phase,” said Amit Gupta, Cardiosense co-founder and CEO, in a statement. “As we complete our validation study for our AI algorithm for cardiac filling pressures and advance towards regulatory submission, John’s leadership will accelerate our mission to expand access to personalized, noninvasive hemodynamic-guided care for the millions living with heart failure and other critical conditions.”

Martin previously held leadership roles at Butterfly Network, where he worked to integrate advanced imaging and monitoring technologies into hospital, clinic, emergency, remote, and home care settings. He also practices at the University of Maryland Vascular Center at Annapolis and founded the Heart Health Foundation, a nonprofit promoting cardiovascular disease education, prevention and early detection.

“Cardiosense is building something truly special at the intersection of AI and medicine,” Martin said. “From the operating room to outpatient care, Cardiosense has the potential to transform how we guide therapy, putting actionable, hemodynamic data in the hands of clinicians, and eventually patients, for self-guided care at home.”

Martin’s appointment follows the recent FDA 510(k) clearance of the CardioTag device, designed for advanced cardiac function monitoring. Cardiosense is pursuing De Novo classification for its first AI algorithm for noninvasive pulmonary capillary wedge pressure estimation. The company’s SEISMIC-HF I study, published in JACC: Heart Failure, found that its noninvasive wearable and AI algorithm can estimate cardiac pressures with accuracy comparable to implantable sensors, without the procedural risks or patient burden of surgery.

Cardiosense aims to broaden access to hemodynamic-guided care, which remains underused; fewer than 1% of eligible patients currently receive implantable sensors.